BTIG analyst Thomas Shrader downgraded Verona Pharma (NASDAQ: VRNA) from Buy to Neutral.The analyst comments: "In our view, it's a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE